Panel Discussion: Defining Clear Regulatory & Scientific Boundaries Between Consumer & Live Biotherapeutics to Strengthen Investment Confidence
- Differentiating regulatory pathways for direct-to-consumer probiotics versus IND-driven live biotherapeutics to align development strategies with approval expectations
- Evaluating how inconsistent product claims and low-quality evidence create skepticism, reducing investor confidence and complicating partnership decision-making
- Establishing clear scientific, clinical, and quality benchmarks to distinguish credible therapeutics from underpowered products and enable stronger commercial positioning